Cargando…
Therapeutic efficacy of a MMAE-based anti-DR5 drug conjugate Oba01 in preclinical models of pancreatic cancer
Pancreatic cancer (PC) is among the most aggressive malignancies associated with a 5-year survival rate of <9%, and the treatment options remain limited. Antibody–drug conjugates (ADCs) are a new class of anticancer agents with superior efficacy and safety profiles. We studied the antitumor activ...
Autores principales: | Zheng, Chao, Zhou, Dongdong, Li, Weisong, Duan, Yanhui, Xu, Minwen, Liu, Jie, Cheng, Jingpei, Xiao, Youban, Xiao, Han, Gan, Tao, Liang, Jianmin, Zheng, Dexian, Wang, Liefeng, Zhang, Shuyong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10148860/ https://www.ncbi.nlm.nih.gov/pubmed/37120688 http://dx.doi.org/10.1038/s41419-023-05820-1 |
Ejemplares similares
-
Preclinical evaluation of a novel antibody-drug conjugate targeting DR5 for lymphoblastic leukemia therapy
por: Zhang, Shuyong, et al.
Publicado: (2021) -
Bivalent EGFR-Targeting DARPin-MMAE Conjugates
por: Karsten, Lennard, et al.
Publicado: (2022) -
Guanidine-modified albumin-MMAE conjugates with enhanced endocytosis ability
por: Yi, Ce, et al.
Publicado: (2023) -
A novel anti-DR5 antibody-drug conjugate possesses a high-potential therapeutic efficacy for leukemia and solid tumors
por: Zhang, Shuyong, et al.
Publicado: (2019) -
Novel Silyl Ether-Based Acid-Cleavable Antibody-MMAE Conjugates with Appropriate Stability and Efficacy
por: Wang, Yanming, et al.
Publicado: (2019)